Cargando…

Guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study

Previous global studies of guselkumab have demonstrated clinical benefits in patients with psoriasis. The aim of this 52‐week, phase 3 study was to evaluate efficacy and safety of guselkumab in Japanese patients with moderate to severe plaque‐type psoriasis. Patients randomly received guselkumab 50...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohtsuki, Mamitaro, Kubo, Hiroshi, Morishima, Hitomi, Goto, Ryosuke, Zheng, Richuan, Nakagawa, Hidemi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175099/
https://www.ncbi.nlm.nih.gov/pubmed/29905383
http://dx.doi.org/10.1111/1346-8138.14504
_version_ 1783361425189634048
author Ohtsuki, Mamitaro
Kubo, Hiroshi
Morishima, Hitomi
Goto, Ryosuke
Zheng, Richuan
Nakagawa, Hidemi
author_facet Ohtsuki, Mamitaro
Kubo, Hiroshi
Morishima, Hitomi
Goto, Ryosuke
Zheng, Richuan
Nakagawa, Hidemi
author_sort Ohtsuki, Mamitaro
collection PubMed
description Previous global studies of guselkumab have demonstrated clinical benefits in patients with psoriasis. The aim of this 52‐week, phase 3 study was to evaluate efficacy and safety of guselkumab in Japanese patients with moderate to severe plaque‐type psoriasis. Patients randomly received guselkumab 50 mg or 100 mg at weeks 0, 4 and every 8 weeks, or placebo with cross‐over to guselkumab 50 mg or 100 mg at week 16. Co‐primary end‐points were the proportion of patients achieving Investigator's Global Assessment (IGA) cleared/minimal (0/1) and 90% or more improvement in Psoriasis Area and Severity Index (PASI‐90) at week 16. Overall, 192 patients were randomized to placebo, guselkumab 50 mg or 100 mg. At week 16, patients in the placebo group were crossed over to guselkumab 50 mg or 100 mg. At week 16, a significantly (P < 0.001) higher proportion of patients receiving guselkumab 50 mg and 100 mg versus placebo achieved IGA 0/1 (92.3% and 88.9% vs 7.8%) and PASI‐90 (70.8% and 69.8% vs 0%). Patients in guselkumab 50 mg and 100 mg groups achieved significant improvement versus placebo in PASI‐75 (89.2% and 84.1% vs 6.3%, P < 0.001) at week 16; improvement was maintained through week 52. Incidences of treatment‐emergent adverse events were comparable among the groups through week 16; the most commonly reported was nasopharyngitis. No new safety concerns were observed until week 52. In conclusion, guselkumab treatment demonstrated superior efficacy over placebo and was well tolerated in Japanese patients with moderate to severe plaque‐type psoriasis.
format Online
Article
Text
id pubmed-6175099
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-61750992018-10-15 Guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study Ohtsuki, Mamitaro Kubo, Hiroshi Morishima, Hitomi Goto, Ryosuke Zheng, Richuan Nakagawa, Hidemi J Dermatol Original Articles Previous global studies of guselkumab have demonstrated clinical benefits in patients with psoriasis. The aim of this 52‐week, phase 3 study was to evaluate efficacy and safety of guselkumab in Japanese patients with moderate to severe plaque‐type psoriasis. Patients randomly received guselkumab 50 mg or 100 mg at weeks 0, 4 and every 8 weeks, or placebo with cross‐over to guselkumab 50 mg or 100 mg at week 16. Co‐primary end‐points were the proportion of patients achieving Investigator's Global Assessment (IGA) cleared/minimal (0/1) and 90% or more improvement in Psoriasis Area and Severity Index (PASI‐90) at week 16. Overall, 192 patients were randomized to placebo, guselkumab 50 mg or 100 mg. At week 16, patients in the placebo group were crossed over to guselkumab 50 mg or 100 mg. At week 16, a significantly (P < 0.001) higher proportion of patients receiving guselkumab 50 mg and 100 mg versus placebo achieved IGA 0/1 (92.3% and 88.9% vs 7.8%) and PASI‐90 (70.8% and 69.8% vs 0%). Patients in guselkumab 50 mg and 100 mg groups achieved significant improvement versus placebo in PASI‐75 (89.2% and 84.1% vs 6.3%, P < 0.001) at week 16; improvement was maintained through week 52. Incidences of treatment‐emergent adverse events were comparable among the groups through week 16; the most commonly reported was nasopharyngitis. No new safety concerns were observed until week 52. In conclusion, guselkumab treatment demonstrated superior efficacy over placebo and was well tolerated in Japanese patients with moderate to severe plaque‐type psoriasis. John Wiley and Sons Inc. 2018-06-15 2018-09 /pmc/articles/PMC6175099/ /pubmed/29905383 http://dx.doi.org/10.1111/1346-8138.14504 Text en © 2018 Janssen Pharmaceutical K.K. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Ohtsuki, Mamitaro
Kubo, Hiroshi
Morishima, Hitomi
Goto, Ryosuke
Zheng, Richuan
Nakagawa, Hidemi
Guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study
title Guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study
title_full Guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study
title_fullStr Guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study
title_full_unstemmed Guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study
title_short Guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study
title_sort guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in japanese patients: efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175099/
https://www.ncbi.nlm.nih.gov/pubmed/29905383
http://dx.doi.org/10.1111/1346-8138.14504
work_keys_str_mv AT ohtsukimamitaro guselkumabanantiinterleukin23monoclonalantibodyforthetreatmentofmoderatetosevereplaquetypepsoriasisinjapanesepatientsefficacyandsafetyresultsfromaphase3randomizeddoubleblindplacebocontrolledstudy
AT kubohiroshi guselkumabanantiinterleukin23monoclonalantibodyforthetreatmentofmoderatetosevereplaquetypepsoriasisinjapanesepatientsefficacyandsafetyresultsfromaphase3randomizeddoubleblindplacebocontrolledstudy
AT morishimahitomi guselkumabanantiinterleukin23monoclonalantibodyforthetreatmentofmoderatetosevereplaquetypepsoriasisinjapanesepatientsefficacyandsafetyresultsfromaphase3randomizeddoubleblindplacebocontrolledstudy
AT gotoryosuke guselkumabanantiinterleukin23monoclonalantibodyforthetreatmentofmoderatetosevereplaquetypepsoriasisinjapanesepatientsefficacyandsafetyresultsfromaphase3randomizeddoubleblindplacebocontrolledstudy
AT zhengrichuan guselkumabanantiinterleukin23monoclonalantibodyforthetreatmentofmoderatetosevereplaquetypepsoriasisinjapanesepatientsefficacyandsafetyresultsfromaphase3randomizeddoubleblindplacebocontrolledstudy
AT nakagawahidemi guselkumabanantiinterleukin23monoclonalantibodyforthetreatmentofmoderatetosevereplaquetypepsoriasisinjapanesepatientsefficacyandsafetyresultsfromaphase3randomizeddoubleblindplacebocontrolledstudy